Patents by Inventor Yeong kyu PARK

Yeong kyu PARK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11955859
    Abstract: The present disclosure relates to a busbar unit for a motor, the busbar unit including: a first terminal; a second terminal provided to be spaced apart from the first terminal in a first direction; a third terminal stacked on the first terminal in a second direction perpendicular to the first direction; a fourth terminal stacked on the second terminal in the second direction; and a holder configured to support the first terminal, the second terminal, the third terminal, and the fourth terminal, thereby obtaining an advantageous effect of simplifying a structure and improving a degree of design freedom and spatial utilization.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: April 9, 2024
    Assignee: Hyundai Mobis Co., Ltd.
    Inventors: Yeong Woo Seo, Jong Bin Park, Jung Kyu Yim
  • Publication number: 20230027819
    Abstract: The present invention relates to a cell-penetrating peptide dimer comprising: a first peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; a second 30Kc19? peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; and a peptide linker connecting the first and second peptide domains, a method for preparing the peptide dimer, a cargo delivery system in which a cargo is conjugated to the dimer; and a use thereof. The cell-penetrating peptide dimer according to the present invention may have excellent cell-penetrating properties, thereby being usefully employed as the cargo delivery system.
    Type: Application
    Filed: August 31, 2022
    Publication date: January 26, 2023
    Inventors: Tai Hyun PARK, Haein LEE, Yeong Kyu PARK, SooHee RYU, Seong Hoon KIM, Hyeong Seok LEE
  • Patent number: 11421009
    Abstract: The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 23, 2022
    Assignee: PANACEA INC.
    Inventors: Jeong-Hyeok Yoon, Byung-Ha Chang, Bong-Seok Jin, Ji Young Bae, Soon Nam Kim, Kyeong Su Park, Yeong kyu Park, Hanjo Kim, Youngju Seo, Wooseong Jeong, KyungTae Kang
  • Publication number: 20210300977
    Abstract: The present invention relates to a cell-penetrating peptide dimer comprising: a first peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; a second 30Kc19a peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; and a peptide linker connecting the first and second peptide domains, a method for preparing the peptide dimer, a cargo delivery system in which a cargo is conjugated to the dimer; and a use thereof. The cell-penetrating peptide dimer according to the present invention may have excellent cell-penetrating properties, thereby being usefully employed as the cargo delivery system.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 30, 2021
    Inventors: Tai Hyun PARK, Haein LEE, Yeong Kyu PARK, SooHee RYU, Seong Hoon KIM, Hyeong Seok LEE
  • Publication number: 20200002396
    Abstract: The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 2, 2020
    Inventors: Jeong-Hyeok Yoon, Byung-Ha Chang, Bong-Seok Jin, Ji Young Bae, Soon Nam Kim, Kyeong Su Park, Yeong kyu Park, Hanjo Kim, Youngju Seo, Wooseong Jeong, KyungTae Kang
  • Patent number: 10479822
    Abstract: The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: November 19, 2019
    Assignee: SUPEX BNP CO., LTD.
    Inventors: Jeong-Hyeok Yoon, Byung-Ha Chang, Bong-Seok Jin, Ji Young Bae, Soon Nam Kim, Kyeong Su Park, Yeong kyu Park, Hanjo Kim, Youngju Seo, Wooseong Jeong, KyungTae Kang
  • Publication number: 20170218038
    Abstract: The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.
    Type: Application
    Filed: November 21, 2014
    Publication date: August 3, 2017
    Inventors: Jeong-Hyeok YOON, Byung-Ha CHANG, Bong-Seok JIN, Ji Young BAE, Soon Nam KIM, Kyeong Su PARK, Yeong kyu PARK, Hanjo KIM, Youngju SEO, Wooseong JEONG, KyungTae KANG